Compare FISI & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FISI | LYEL |
|---|---|---|
| Founded | 1817 | 2018 |
| Country | United States | United States |
| Employees | 631 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 643.4M | 556.1M |
| IPO Year | N/A | 2021 |
| Metric | FISI | LYEL |
|---|---|---|
| Price | $34.94 | $21.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $37.00 | $30.60 |
| AVG Volume (30 Days) | ★ 93.1K | 76.7K |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.22 | $8,712.13 |
| P/E Ratio | $9.36 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.41 | $0.39 |
| 52 Week High | $35.67 | $45.00 |
| Indicator | FISI | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 63.95 | 44.11 |
| Support Level | $26.91 | $20.72 |
| Resistance Level | $35.49 | $26.89 |
| Average True Range (ATR) | 0.80 | 1.62 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 67.50 | 7.84 |
Financial Institutions Inc operates through its subsidiaries, providing full range of banking services to consumer, commercial and municipal customers in Western and Central New York, and commercial loans in the Mid-Atlantic region, through a loan production office in Ellicott City, Maryland. It offers a broad range of loans including commercial business and revolving lines of credit, commercial mortgages, equipment loans, residential mortgage loans and home equity loans and lines of credit, automobile loans and personal loans. It operates in single segment of Banking.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.